- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06134973
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of Hepatocellular Carcionoma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hepatocellular Carcinoma (HCC)is one of the cancers with high morbidity and mortality in the world , and the incidence of liver cancer in China is particularly serious. In 2020, there will be 410,000 new cases of liver cancer in China, accounting for 42.5% of the world. There were 391,000 deaths, ranking fifth in the incidence of malignant tumors and second in the fatality rate . Most patients with primary liver cancer have insidious onset and have reached the middle and late stage when diagnosed. At this time, the treatment of liver cancer is few, the prognosis is poor, and the mortality is high.Early detection and treatment are of great significance to improve the survival rate of patients with liver cancer, and the 5-year survival rate after early liver cancer (BCLC stage 0/A) can reach more than 60%. However, the diagnosis rate of early liver cancer in China is only 30%. In other countries, early diagnosis rates can be increased to more than 60% by monitoring high-risk populations. It can be seen that close monitoring of the pre-cancer stage is the key to early diagnosis and early treatment of HCC.
Identifying people at high risk for cancer development is the premise of cancer Surveillance and the biggest difference from conducting tumor Screening in the general population. Compared with many other common cancers, Targets for liquid biopsies come in many forms, including genetics-based tests for gene mutations, and epigenetic-based tests for methylation. Since no specific gene mutation events directly related to cancerization have been found in liver cancer, the effect of searching for biomarkers along this route is limited. Therefore, detecting early liver cancer from the epigenetic level has become another way worth exploring.
In the epigenetic mechanism, DNA methylation is an important gene regulation mode, which is closely related to the occurrence and development of tumors. More importantly, abnormal methylation of cancer-related genes often occurs in the early stage of cancer development, so DNA methylation signals are considered as potential markers for early tumor screening [14]. In addition, methylation modification is tissue-specific in different tumors and can even be used to locate the primary tissue of cancer, which is an ideal molecular marker for tumor early screening [15]. Therefore, ctDNA, which carries tumor cell-specific methylation information, can be used as a target for liquid biopsy of liver cancer, providing an innovative path for early diagnosis of HCC develops gradually on the basis of clear causes, such as typical hepatitis, cirrhosis to liver cancer "three steps". These characteristics determine the target population for early diagnosis of HCC, which can be found in the medical treatment of various chronic liver diseases. Making full use of these precancerous risk factors and identifying high-risk groups of liver cancer as surveillance objects will help improve the detection rate of cancer and obtain a better benefit-cost ratio.
Intrahepatic nodules are the disorder of hepatic trabecular arrangement caused by fibrous tissue hyperplasia. Their formation indicates the progression of liver injury and is also an important stage of precancerous lesions. Pathologically, nodules can be divided into stages such as regenerated nodules, low grade and high grade atypical hyperplasia, and adenoma according to their proximity to cancer, but the standards and terminology are still difficult to be unified, and pathological diagnosis requires obtaining samples through liver puncture, which is not widely used in clinical practice. In this case, the size of the intrahepatic nodules detected by ultrasound becomes an important basis for liver cancer risk stratification. Taking the current guidelines for diagnosis and treatment of liver cancer in China as an example, whether the nodule diameter is greater than 2 cm is the main basis for classification and diagnosis: for nodules less than 2 cm, at least two imaging evidences are required to confirm liver cancer; For nodules larger than 2 cm, only one item is needed. In addition, stratified analysis based on the size of intrahepatic nodules is also a framework for objective evaluation of the role of tumor markers. Alpha-fetoprotein (AFP), a traditional serum marker for hepatocellular carcinoma, has a sensitivity of 72-87% in advanced hepatocellular carcinoma. But for early-stage liver cancer smaller than 2 cm, its sensitivity is only 30-50%.
In view of the shortcomings of traditional serological markers with few types and low specificity, many important advances have been made in the application of molecular detection techniques based on omics to cancer diagnosis and screening. The liquid biopsy technology based on high throughput sequencing can detect specific abnormal signals in a small amount of Circulating Tumor DNA (ctDNA) in human peripheral blood, thus promoting the technological innovation of tumor early screening.
Targets for liquid biopsies come in many forms, including genetics-based tests for gene mutations, and epigenetic-based tests for methylation. Since no specific gene mutation events directly related to cancerization have been found in liver cancer, the effect of searching for biomarkers along this route is limited. Therefore, detecting early liver cancer from the epigenetic level has become another way worth exploring.
In the epigenetic mechanism, DNA methylation is an important gene regulation mode, which is closely related to the occurrence and development of tumors. More importantly, abnormal methylation of cancer-related genes often occurs in the early stage of cancer development, so DNA methylation signals are considered as potential markers for early tumor screening . In addition, methylation modification is tissue-specific in different tumors and can even be used to locate the primary tissue of cancer, which is an ideal molecular marker for tumor early screening . Therefore, ctDNA, which carries tumor cell-specific methylation information, can be used as a target for liquid biopsy of liver cancer, providing an innovative path for early diagnosis of HCC.
Although liquid biopsy shows promising application in the early diagnosis of HCC, most results are based on retrospective studies. According to the steps of marker research and development, future and multi-center studies are needed to verify it. In this project, we will rely on the team and work foundation of the key discipline of digestion (Liver disease), and cooperate with BGI Shenzhen BGI Medical Laboratory to carry out liquid biopsy based on methylation, and evaluate its feasibility for liver cancer monitoring through prospective studies. Promote the realization of early detection, diagnosis and treatment of HCC.
The risk assessment model of liver cancer was established to identify the high-risk groups of liver cancer. A prospective cohort study was conducted to evaluate the predictive ability of liquid biopsy technology for liver cancer occurrence, and to verify the performance and application prospects of this novel genetic detection technology in liver cancer monitoring.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Fengmei Wang, PhD
- Phone Number: 15522242696
- Email: wangfengmeitj@126.com
Study Contact Backup
- Name: Fang Wang, MD
- Phone Number: +8618649047892
- Email: yaoywang@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300170
- Recruiting
- 王芳
-
Contact:
- Fang Wang, doctor
- Phone Number: +8618649047892
- Email: yaoywang@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Enrollment criteria: All patients who were admitted to our hospital over 18 years old and found intrahepatic nodules by abdominal ultrasound and consented to join the prospective cohort study of intrahepatic nodules monitoring. Enrolled patients were grouped according to the maximum diameter of nodules in the live and were divided into nodular group (diameter less than 2 cm) and macronodular group (diameter 2-3 cm).
Outcome events: Intrahepatic nodules were diagnosed as cancerous nodules. Follow-up: Patients who found intrahepatic nodules but were not confirmed by imaging or pathology were followed up every 2-3 months with imaging combined with serum AFP levels until the outcome events were observed.
Description
Inclusion Criteria:
- Patients diagnosed as chronic liver disease, including but not limited to chronic hepatitis B, chronic hepatitis C, fatty liver;
- Intrahepatic nodules detectable by ultrasound;
- Unlimited number of nodules;
- The patient has signed an informed consent form.
Exclusion Criteria:
- Previously diagnosed malignant tumors;
- Patients who are unable to cooperate with venous blood sampling;
- According to the judgment of the investigator, the participants are not suitable to participate in this study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Nodular group
nodules less than 2 cm in diameter
|
ultrasonic testing
|
Macronodular group
nodules between 2-3 cm in diameter
|
ultrasonic testing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The establishment of risk assessment model
Time Frame: 6-12 months
|
The risk assessment model of liver cancer was established to identify the high-risk groups of HCC.
|
6-12 months
|
Application prospect of liquid biopsy technique in monitoring HCC in high risk population
Time Frame: 12-24 months
|
To evaluate the potential application of liquid biopsy techniques for liver cancer surveillance in high-risk populations through a prospective cohort
|
12-24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fengmei Wang, PhD, Tianjin Third Central Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Fangwang03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on ultrasonic testing
-
Brock UniversityDr. Peter C. Fritz, Periodontal Wellness & Implant SurgeryCompletedPeriodontitis | Periodontal PocketCanada
-
The First Affiliated Hospital of Xiamen UniversityCompleted
-
Second Affiliated Hospital, School of Medicine,...Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; First Affiliated Hospital of Wenzhou Medical UniversityUnknownRenal Insufficiency | Renal TransplantationChina
-
Universidad de GranadaCompleted
-
Ethicon Endo-SurgeryChildren's Hospital Medical Center, CincinnatiTerminated
-
ZetrOZ, Inc.State University of New York - Upstate Medical UniversityTerminated
-
University of OsloRecruiting
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Cukurova UniversityCompleted
-
Vejle HospitalCompleted